Poland· PL-100190167

Diabetofort

A medicinal product containing produkt złożony, registered in Poland by Przedsiębiorstwo Farmaceutyczne "Leki Natury" Tadeusz Polański Sp. z o.o..

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedDiabetofortATC—REGISTER NO.PL-100190167PACKS LISTED1CHECKEDSeptember 27, 2026

The record

At a glance

URPL (Poland)
Active substance
Produkt złożony
Manufacturer
Przedsiębiorstwo Farmaceutyczne "Leki Natury" Tadeusz Polański Sp. z o.o.
Country
Poland (PL)
ATC code
—
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909990699346

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3f8a296f-9b2c-46ab-a1b6-d171a77c60e3
GET /v1/drugs/3f8a296f-9b2c-46ab-a1b6-d171a77c60e3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Płyn doustny",
  "source": "urpl",
  "strength": "-",
  "packaging": "05909990699346 ¦ OTC ¦ 50032\n1 butelka 100 g",
  "substance": "Phaseoli pericarpium 30 cz. + Betulae folium 20 cz. + Agropyri rhizoma 20 cz. + Rubi fruticosi folium 20 cz. + Rosae fructus 10 cz. + Etanol 70% (V/V)",
  "common_name": "Produkt złożony",
  "pl_product_id": "100190167",
  "pozwolenie_nr": "15510",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about produkt złożony.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.